Hostname: page-component-586b7cd67f-l7hp2 Total loading time: 0 Render date: 2024-11-27T18:23:16.336Z Has data issue: false hasContentIssue false
  • English
  • Français

Industry and Academic Medicine: A Dangerous Liaison?

Published online by Cambridge University Press:  02 December 2014

John W. Norris
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Editorial
Information
Canadian Journal of Neurological Sciences , Volume 31 , Issue 1 , February 2004 , pp. 5 - 6
Copyright
Copyright © The Canadian Journal of Neurological 2004

References

1.Lenzer, J.Alteplase for stroke: money and optimistic claims buttressthe brain attack: campaign. Br Med J 2002;324:723–729.Google Scholar
2.Editorial. The invisible hand of the marketing department. CMAJ 2002;167:5.Google Scholar
3.Wazana, A.Physicians and the pharmaceutical industry. JAMA 2000;283:373–380.Google Scholar
4.Choudhry, NK, Stelfox, HT, Detsky, AS.Relationships betweenauthors of clinical practice guidelines and the pharmaceutical industry. JAMA 2002;287:612–617.CrossRefGoogle ScholarPubMed
5.Drazen, JM, Curfman, GD.Financial associations of authors. N Engl J Med 2002;346:1901–1902.Google Scholar
6.Relman, AS.Financial associations of authors. N Engl J Med 2002;347:1043.Google Scholar
7.Montaner, JSG, O’Shaughnessy, MV, Schechter, MT.Industry-sponsored clinical research: a double-edged sword. Lancet 2001;358:1893–1894.Google Scholar
8.Bodenheimer, T.Uneasy alliance-clinical investigators and thepharmaceutical industry. N Engl J Med 2000;324:1539–1544.CrossRefGoogle Scholar
9.Drazen, JM.Institutions, contracts, and academic freedom. N Engl J Med 2002;347:1362–1363.CrossRefGoogle ScholarPubMed